跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
OCTREOTIDE FOR INJECTABLE SUSPENSION - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
OCTREOTIDE FOR INJECTABLE SUSPENSION
Authorized
STANDARD
OCTREOTIDE FOR INJECTABLE SUSPENSION
teva canada limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
50e1c1311acfb6cb
Company
teva canada limited
Type
Standard
Approval Details
Approval Id
50e1c1311acfb6cb
Drug Approval Canada Name
OCTREOTIDE FOR INJECTABLE SUSPENSION
Product Name
OCTREOTIDE FOR INJECTABLE SUSPENSION
Status
Marketed
Status Date
2021-08-09
Original Market Date
2021-08-09
Din
02503778
Drug Class
Human
Dosage Form
Kit , Powder For Suspension, Sustained-Release
Route Of Administration
Intramuscular
Schedule
Prescription
Ahfs
92:00.00
Atc Original
H01CB02 OCTREOTIDE
Atc Name
h 01 cb 02
Aig Number
0121548006
Company Name
teva canada limited
Company Address
30 Novopharm Court, Toronto, Ontario, Canada, M1B 2K9
Active Ingredients
OCTREOTIDE (OCTREOTIDE ACETATE)
20 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
50e1c1311acfb6cb
Type
Standard
Back to Health Canada Approvals